Literature DB >> 34188599

History of Myasthenia Gravis Revisited.

Feza Deymeer1.   

Abstract

The first description of myasthenia gravis (MG) was given by Thomas Willis in 1672. MG was the focus of attention after mid-nineteenth century and a great amount of information has been accumulated in a span of 150 years. The aim of this review is to convey this information according to a particular systematic and to briefly relate the experience of Istanbul University. MG history was examined in four periods: 1868-1930, 1930-1960, 1960-1990, and 1990-2020. In the first period (1868-1930), all the clinical characteristics of MG were defined. Physiological/pharmacological studies on the transmission at the neuromuscular junction were initiated, and the concept of repetitive nerve stimulation emerged. A toxic agent was believed to be the cause of MG which appeared to resemble curare intoxication. Association of MG with thymus was noticed. No noteworthy progress was made in its treatment. In the second period (1930-1960), acetylcholine was discovered to be the transmitter at the neuromuscular junction. Repetitive nerve stimulation was used as a diagnostic test. The autoimmune nature of MG was suspected and experiments to this end started to give results. The hallmark of this period was the use of anticholinesterases and thymectomy in the treatment of MG. The third period (1960-1990) can probably be considered a revolutionary era for MG. Important immunological mechanisms (acetylcholine receptor isolation, discovery of anti-acetylcholine receptor antibodies) were clarified and the autoimmune nature of MG was demonstrated. Treatment modalities which completely changed the prognosis of MG, including positive pressure mechanic ventilation and corticosteroids as well as plasma exchange/IVIg and azathioprine, were put to use. In the fourth period (1990-2020), more immunological progress, including the discovery of anti-MuSK antibodies, was achieved. Videothoracoscopic thymectomy reduced the morbidity and mortality rate associated with surgery. New drugs emerged and clinical trials were performed. Valuable guidelines were published. In the last part of the review, the experience in MG of Istanbul University, a pioneer in Turkey, is related. Copyright:
© 2021 Turkish Neuropsychiatric Society.

Entities:  

Keywords:  Istanbul University; Myasthenia gravis; history; treatment

Year:  2020        PMID: 34188599      PMCID: PMC8214743          DOI: 10.29399/npa.27315

Source DB:  PubMed          Journal:  Noro Psikiyatr Ars        ISSN: 1300-0667            Impact factor:   1.339


  100 in total

1.  Practice parameter for repetitive nerve stimulation and single fiber EMG evaluation of adults with suspected myasthenia gravis or Lambert-Eaton myasthenic syndrome: summary statement.

Authors: 
Journal:  Muscle Nerve       Date:  2001-09       Impact factor: 3.217

2.  Myasthenia gravis: current status of pathogenesis, clinical manifestations, and management.

Authors:  D GROB
Journal:  J Chronic Dis       Date:  1958-10

3.  The history of myasthenia gravis.

Authors:  G KEYNES
Journal:  Med Hist       Date:  1961-10       Impact factor: 1.419

Review 4.  Autoimmune thyroid disease.

Authors:  Anthony P Weetman
Journal:  Autoimmunity       Date:  2004-06       Impact factor: 2.815

5.  How electric fish became sources of acetylcholine receptor.

Authors:  John Keesey
Journal:  J Hist Neurosci       Date:  2005-06       Impact factor: 0.529

6.  Myasthenia Gravis: A Case in which Fatigue of the Forearm Muscles could induce Paralysis of the Extra-ocular Muscles.

Authors:  M B Walker
Journal:  Proc R Soc Med       Date:  1938-05

7.  The use of ACTH and corticosteroids in myasthenia gravis.

Authors:  G Genkins; P Kornfeld; K E Osserman; T Namba; D Grob; N G Brunner
Journal:  Ann N Y Acad Sci       Date:  1971-09-15       Impact factor: 5.691

Review 8.  Intravenous immunoglobulin for myasthenia gravis.

Authors:  Philippe Gajdos; Sylvie Chevret; Klaus V Toyka
Journal:  Cochrane Database Syst Rev       Date:  2012-12-12

9.  A clinical therapeutic trial of cyclosporine in myasthenia gravis.

Authors:  R S Tindall; J T Phillips; J A Rollins; L Wells; K Hall
Journal:  Ann N Y Acad Sci       Date:  1993-06-21       Impact factor: 5.691

Review 10.  Unravelling the pathogenesis of myasthenia gravis.

Authors:  Angela Vincent
Journal:  Nat Rev Immunol       Date:  2002-10       Impact factor: 53.106

View more
  1 in total

1.  Subxiphoid and subcostal arch versus unilateral video-assisted thoracic surgery approaches to thymectomy for myasthenia gravis.

Authors:  Yujiang Li; Zhenhui Huang; Wohua Han; Jingquan Yuan; Ruiwen Xie; Guobiao Cheng; Xi'an Huang; Yuliang Guo; Mongying Sun; Yali Liu; Xu Wu; Jianping Zhou
Journal:  Surg Today       Date:  2022-07-01       Impact factor: 2.549

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.